6.965
Ginkgo Bioworks Holdings Inc stock is traded at $6.965, with a volume of 459.49K.
It is up +2.06% in the last 24 hours and down -12.39% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
See More
Previous Close:
$6.79
Open:
$6.7
24h Volume:
459.49K
Relative Volume:
0.41
Market Cap:
$469.36M
Revenue:
$141.31M
Net Income/Loss:
$-297.87M
P/E Ratio:
-1.2914
EPS:
-5.3933
Net Cash Flow:
$-168.20M
1W Performance:
-9.41%
1M Performance:
-12.39%
6M Performance:
-23.00%
1Y Performance:
-47.42%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DNA
Ginkgo Bioworks Holdings Inc
|
6.97 | 457.24M | 141.31M | -297.87M | -168.20M | -5.3933 |
|
VRTX
Vertex Pharmaceuticals Inc
|
515.49 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
805.31 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
993.60 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
215.34 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
362.60 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale - Stock Titan
How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing - Stock Traders Daily
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Moomoo
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Just Slashed This Year's Revenue Estimates By 22% - simplywall.st
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Aug 2026 $DNA - MarketBeat
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis - finance.biggo.com
Ginkgo Bioworks Holdings Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Slammed 36% But Getting In Cheap Might Be Difficult Regardless - 富途牛牛
Ginkgo Bioworks (NYSE:DNA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Ginkgo Bioworks Q2 Earnings Call Highlights - MarketBeat
DNA Downgraded by TD Cowen -- Price Target Lowered to $9.00 - GuruFocus
TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9 - Moomoo
TD Cowen cuts Ginkgo Bioworks stock rating on growth uncertainty - Investing.com India
TD Cowen Downgrades Ginkgo Bioworks to Hold From Buy, Adjusts Price Target to $9 From $12 - marketscreener.com
TD Cowen cuts Ginkgo Bioworks stock rating on growth uncertainty By Investing.com - Investing.com Australia
TD Cowen Downgrades Ginkgo Bioworks Holdings Inc (DNA) to Hold - StreetInsider
Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ginkgo Bioworks Holdings, Inc. 2Q 2026: Revenue ($46.95M), Net income ($46.71M), EPS ($0.75) — 10-Q Summary - TradingView
Biosecurity sale shapes Ginkgo Bioworks (NYSE: DNA) Q2 2026 results - Stock Titan
Ginkgo Bioworks Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:DNA) 2026-08-06 - Seeking Alpha
Ginkgo Bioworks (NYSE:DNA) Trading Down 9.6%Here's What Happened - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT) - The Globe and Mail
BlackRock, Inc. Buys Ginkgo Bioworks Holdings Inc (DNA) -- Shares Look 32% Overvalued on GF Value - GuruFocus
Earnings call transcript: Ginkgo Bioworks Q2 2026 revenue miss weighs on shares - Investing.com Canada
Ginkgo Bioworks : Q2 2026 Results Presentation - marketscreener.com
Ginkgo Bioworks (NYSE:DNA) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Ginkgo Bioworks (DNA) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 FY2026 earnings call transcript - Yahoo Finance
Ginkgo Bioworks reports Q2 2026 revenue $20.2M, GAAP net loss $57.3M, Adjusted EBITDA ($36.3M) - TradingView
Ginkgo Bioworks (NYSE: DNA) posts Q2 loss, wins $47M lab deal - Stock Titan
(DNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ginkgo Bioworks earnings beat by $0.13, revenue fell short of estimates - Investing.com Canada
Ginkgo Bioworks partners with Acies Bio to license Aspergillus niger strains for protein production - Bitget
Ginkgo Bioworks Holdings Inc (DNA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5. - Moomoo
Ginkgo Bioworks (DNA) CEO Jason R. Kelly receives over 300k new RSUs - Stock Titan
Ginkgo Bioworks (NYSE: DNA) plans Q2 2026 results presentation and Q&A - Stock Titan
Ginkgo Bioworks (DNA) to Release Earnings on Thursday - MarketBeat
Ginkgo Bioworks Holdings Inc (DNA) Balance Sheet - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.445|Chg%:+0.085 - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Income Statement - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.761| - TradingKey
ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Cash Flow - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):